By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that its first-quarter 2010 net loss swelled 18 percent, as the firm's expenses for R&D, sales, and other purposes rose but its revenues continued to be insignificant.

The Tel Aviv, Israel-based firm, which uses an in silico prediction and selection platform for discovering drug and diagnostic candidates, had revenues of $125,000 for the three-month period ended Mar. 31, compared to no revenue for last year's first quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.